Context Introduction of novel agents for the management of advanced prostate cancer
provides a range of treatment options with notable benefits for men with metastatic castration …

In the last decade, immunotherapy has revolutionized the treatment landscape of several
hematological and solid malignancies, reporting unprecedented response rates …

Background Patients with castration-resistant prostate cancer derive only modest clinical
benefit from available therapies. Blockade of the inhibitory programmed death 1 (PD-1) …

Sipuleucel-T, an autologous cellular immunotherapy manufactured from antigen-presenting
cells primed to recognize prostatic acid phosphatase, was the first immunotherapy product …

Immune checkpoint inhibitors propelled the field of oncology with clinical responses in many
different tumor types. Superior overall survival over chemotherapy has been reported in …

Introduction: Pharmacological inhibition of immune checkpoint receptors or their ligands
represents a transformative breakthrough in the management of multiple cancers. However …

Immunotherapy is considered as an effective method for cancer treatment owing to the
induction of specific and long-lasting anti-cancer effects. Immunotherapeutic strategies have …

Abstract Purpose of Review Despite significant progress, patients with metastatic prostate
cancer continue to have poor prognosis. Immunotherapy has revolutionized cancer care for …

Prostate cancer remains one of the leading causes of cancer death in men worldwide. In the
past decade, several new treatments for advanced prostate cancer have been approved …

Immunotherapy is rapidly transforming cancer care across a range of tumor types. Although
Sipuleucel-T represented the first successful vaccine for the treatment of established cancer …